Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/14321
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes
Author: Hutchinson, M.
Menelaou, A.
Foster, D.
Coller, J.
Somogyi, A.
Citation: British Journal of Clinical Pharmacology, 2004; 57(3):287-297
Publisher: Blackwell Publishing Ltd
Issue Date: 2004
ISSN: 0306-5251
1365-2125
Statement of
Responsibility: 
Mark R. Hutchinson, Andrew Menelaou, David J. R. Foster, Janet K. Coller and Andrew A. Somogyi
Abstract: AIM: To determine the Michaelis-Menten kinetics of hydrocodone metabolism to its O- and N-demethylated products, hydromorphone and norhydrocodone, to determine the individual cytochrome P450 enzymes involved, and to predict the in vivo hepatic intrinsic clearance of hydrocodone via these pathways. METHODS: Liver microsomes from six CYP2D6 extensive metabolizers (EM) and one CYP2D6 poor metabolizer (PM) were used to determine the kinetics of hydromorphone and norhydrocodone formation. Chemical and antibody inhibitors were used to identify the cytochrome P450 isoforms catalyzing these pathways. Expressed recombinant cytochrome P450 enzymes were used to characterize further the metabolism of hydrocodone. RESULTS: Hydromorphone formation in liver microsomes from CYP2D6 EMs was dependent on a high affinity enzyme (Km = 26 µm) contributing 95%, and to a lesser degree a low affinity enzyme (Km = 3.4 mm). In contrast, only a low affinity enzyme (Km = 8.5 mm) formed this metabolite in the liver from the CYP2D6 PM, with significantly decreased hydromorphone formation compared with the livers from the EMs. Norhydrocodone was formed by a single low affinity enzyme (Km = 5.1 mm) in livers from both CYP2D6 EM and PM. Recombinant CYP2D6 and CYP3A4 formed only hydromorphone and only norhydrocodone, respectively. Hydromorphone formation was inhibited by quinidine (a selective inhibitor of CYP2D6 activity), and monoclonal antibodies specific to CYP2D6. Troleandomycin, ketoconazole (both CYP3A4 inhibitors) and monoclonal antibodies specific for CYP3A4 inhibited norhydrocodone formation. Extrapolation of in vitro to in vivo data resulted in a predicted total hepatic clearance of 227 ml h1 kg1 and 124 ml h1 kg1 for CYP2D6 EM and PM, respectively. CONCLUSIONS: The O-demethylation of hydrocodone is predominantly catalyzed by CYP2D6 and to a lesser extent by an unknown low affinity cytochrome P450 enzyme. Norhydrocodone formation was attributed to CYP3A4. Comparison of recalculated published clearance data for hydrocodone, with those predicted in the present work, indicate that about 40% of the clearance of hydrocodone is via non-CYP pathways. Our data also suggest that the genetic polymorphisms of CYP2D6 may influence hydrocodone metabolism and its therapeutic efficacy.
Keywords: Microsomes, Liver; Humans; Hydrocodone; Hydromorphone; Cytochrome P-450 Enzyme System; Cytochrome P-450 CYP2D6; Analgesics, Opioid; Oxidation-Reduction; Cytochrome P-450 CYP3A
Description: The definitive version is available at www.blackwell-synergy.com
RMID: 0020031979
DOI: 10.1046/j.1365-2125.2003.02002.x
Published version: http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2125.2003.02002.x
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.